ACTmed, a joint venture between Canon Medical Systems Corporation (Headquarters: Otawara, Tochigi Prefecture, Japan; President and CEO: Toshio Takiguchi), and ACT Genomics (Headquarters: Taipei, Taiwan, CEO: Hua Chien Chen) has established an analysis laboratory named “Shonan iPark Laboratory” in “Shonan Health Innovation Park”. With the laboratory, ACTmed will offer precision cancer medicine to fulfill the clinical needs and drug development activities in Japan, making it possible to provide comprehensive services to quickly address requests from clients and promptly respond to their inquiries. Full-scale operation is scheduled to commence in July 2019.
ACT Genomics will continue to provide medical informatics solution through its AI-powered bioinformatics pipelines to ACTmed, which enable the joint venture to provide medical interpretation that is created based on clinical databases of genetic information specifically for Asian populations as well as other clinical information curated from available database. “We are excited to see the launch and to facilitate precision medicine service for biomarker-driven clinical trials in oncology and treatment identification for cancer patients in Japan,” said Dr. Hua Chien Chen at ACT Genomics.
In addition to the NGS-lab launched in Japan, ACT Genomics expects to open another new lab in Hong Kong in June 2019, to continue the expansion and focus on Asia market. As the only Asian diagnostic company in the US Friends of Cancer Research-led TMB harmonization project, ACT Genomics has developed proprietary computational algorithm for Tumor Mutational Burden (TMB) calculation with tissue-based ACTOnco® to support increasing demands from both clinical research and diagnostic activities in most of the major Asian cities in Japan, China, Taiwan, Hong Kong, Singapore and South East Asia countries and regions.
SOURCE ACT Genomics